Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Transcept Pharmaceuticals Resubmits Intermezzo New Drug Application

By Pharmaceutical Processing | January 18, 2011

Transcept Pharmaceuticals, Inc. today announced that it has resubmitted
its New Drug Application (NDA) to the FDA seeking approval of Intermezzo for
use as needed for the treatment of insomnia when a middle of the night
awakening is followed by difficulty returning to sleep.

Transcept expects that the Intermezzo NDA resubmission, if
accepted and deemed complete by the FDA, will be subject to a Class 2 six-month
review.

The Intermezzo resubmission package is intended to address
issues raised in the October 2009 FDA Complete Response Letter. New information
contained in the resubmission package includes data and analyses from the
recently completed Intermezzo highway driving study, a comparative review of
data from previous driving studies of sleep aids and other medications, and
redesigned product packaging and instructional tools. The resubmission also
includes a recent epidemiology study that demonstrates the widespread use of 7
to 8 hour hypnotic drugs in the middle of the night, despite the fact that
these products have been approved only for bedtime dosing.

“If approved, we anticipate that Intermezzo will be the
first prescription sleep aid for use as-needed for the treatment of insomnia when
a middle of the night awakening is followed by difficulty returning to
sleep,” said Glenn A. Oclassen, President and Chief Executive Officer of
Transcept Pharmaceuticals. “We plan to work closely with the FDA through
the resubmission process and are fully committed to making this important
therapeutic option available to insomnia patients.”

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE